Global insights driving the market strategies of tomorrow.

Lilly's (LLY.US) new blockbuster drug "tirzepatide" has filed its fifth NDA in China

Market IntelSunday, Dec 15, 2024 3:30 am ET

1min read

On December 14, the latest public information on the website of the National Medical Products Administration's Drug Review Center (CDE) showed that Eli Lilly's (LLY.US) blockbuster drug tirzepatide, a dual agonist of GIP/GLP-1 receptors, has been accepted for a new indication application. The specific indication has not been disclosed. According to the CDE's website, this is the fifth submission of tirzepatide for marketing authorization in China, of which two have been approved by the NMPA previously.Tirzepatide is a weekly injectable drug that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Currently, Eli Lilly is also continuously exploring the application of tirzepatide in various indications.According to Eli Lilly's pipeline information on its website, tirzepatide is also in phase 3 clinical trials for multiple indications, including reducing the incidence and mortality of obesity and reducing adverse cardiovascular outcomes in patients with type 2 diabetes.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.